Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$11.62M$11.62Mderived+38.8% vs Q4 2021 Net Income-$9.98M-$9.98MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$8,176,000+44.5% Operating Incomederived-$9,439,000N/M Operating Cash Flowderived-$10,983,000N/M Free Cash Flowderived-$11,029,000N/M Margins · derivedGross margin70.3%+2.8 pt vs Q4 2021
Operating margin-81.2%+10.2 pt vs Q4 2021
Net margin-85.9%+17.1 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 23, 2023 · 82 d after period end